Invests in
Locations:
Min Investment:
$1,000,000.00Max Investment:
$20,000,000.00Target Investment:
$5,000,000.00
Skills
Education
- I
- I
- LM
Lists including Randolph
Work Experience
2024
Chief Executive Officer
2024
Co-Founder
2023
2021
Co-Founder
2021
2019
Member Of The Board Of Advisors
2019
Co-Founder
2019
2018
Independent Board Director
2018
Outstanding veterinary gut health company.
2019 - 2022
Independent Board Director
2019 - 2022
Highly innovative vaccine platform company.
2020 - 2022
Venture Partner
2020 - 2022
1997 - 2018
VP, Global Head of Business Development & Licensing Animal Health
2017 - 2018
Responsible for licensing and acquisition of technology, pipeline projects and approved products for the Animal Health Business. Our global team partners with academic institutes, universities and companies of all sizes to bring innovative medicines and vaccines to our customers. In addition we ensure effective management of our strategic alliance partners.
Managing Director, BI Veterinary Research Center GmbH & Co. KG
2013 - 2017
Member of the BIVRC management board responsible for R&D.
VP, Global Head of R&D Animal Health
2007 - 2016
Globally responsible for identification, development and registration of new pharmaceutical and vaccine products for the Animal Health business. Managing all global activities relating to research, development, regulatory affairs, R&D QA and pharmacovigilance. Overseeing and managing an international R&D organization with major locations in the US, EU, China, Mexico and Japan. Responsible for developing and implementing the R&D strategy, including sites, technologies, pipeline, processes, external collaborations and human capital. As a member of the Animal Health Global Executive Management Board share overall responsibility for animal health business.
Head of Global R&D Site Integration Animal Health
2006 - 2007
Senior Principal Scientist Cardiovascular Diseases
2003 - 2006
Leading drug discovery projects (NCEs and NBEs) in the area of congestive heart failure and hypertension. Leading and managing a group of scientists (PhDs and junior scientist). Member of the Cardiovascular Drug Discovery Leadership team and of the Cardiovascular Clinical Expert Group (the senior leadership team for Cardiovascular Disease drug development). Part of the US post approval Medico-Marketing team for Pharmacology.
Principal Scientist Cardiovascular Diseases
2001 - 2003
Leading drug discovery projects (NCEs, NBEs and Gene Therapy) in the area of angiogenesis and acute myocardial infarction. Leading and managing a group of scientists (PhDs and junior scientist). Driving innovation by proposing and validating novel drug discovery targets and strong contribution to delineating a novel R&D strategy for Cardiovascular Disease drug discovery.
Senior Scientist General Pharmacology
1997 - 2000
Leading a laboratory in the area of cardiovascular physiology and pharmacology. Evaluating novel drug candidates with respect to cardiovascular safety and ancillary efficacy (hemodynamics and electrophysiology).